Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | PLK1 | P53350 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | GALR3 | O60755 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385421 | 0.84 | TRPV1 (0.76) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL4326686 | 0.84 | TRPV1 (0.76) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL8363015 | 0.84 | TRPV1 (0.76) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL22556340 | 0.83 | TRPV1 (0.84) | TRPV1PLK1RARB | |
| SCHEMBL10112878 | 0.83 | TRPV1 (0.74) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL10803698 | 0.83 | TRPV1 (0.74) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL8642579 | 0.83 | TRPV1 (0.61) | TRPV1KDM4ENPC1GALR3RAB9A | |
| SCHEMBL13181111 | 0.82 | TRPV1 (0.88) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL2915657 | 0.82 | TRPV1 (0.72) | TRPV1KDM4EPLK1NPC1GALR3 | |
| SCHEMBL7302615 | 0.82 | NR1H4 (0.76) | TRPV1KDM4EPLK1NPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2021-10-05 | — | — | US | disclosed |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS | 2019-10-31 | — | — | US | disclosed |
| WO-2018112077-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | TRPV1 1026/4885KDM4E 4599/4885PLK1 4494/4885 |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | TRPV1 1026/4885KDM4E 4599/4885PLK1 4494/4885 |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CERS2, DEGS1, SMPD1 | TRPV1 1026/4885KDM4E 4599/4885PLK1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.